HOSPITAL UNIVERSITARIO DE FUENLABRADA

Their core work

Hospital Universitario de Fuenlabrada is a public university hospital near Madrid specializing in clinical oncology research, with a strong focus on pancreatic cancer. Their H2020 work centers on translating laboratory cancer research into clinical treatments — from personalized therapy using patient-derived xenograft (avatar) mouse models to scaling up nanomedicine for early-phase clinical trials. They serve as a clinical partner bridging preclinical research and patient care, contributing biobank access, clinical trial infrastructure, and oncology expertise to European consortia.

What they specialise in

How they've shifted over time

Their trajectory shows a clear progression from fundamental personalized oncology (AVATAR, 2015) toward applied nanomedicine manufacturing (NoCanTher, 2016) and shared research infrastructure (EDIReX, 2018). Early work focused on genomic integration and avatar mouse models for individual patient treatment; later involvement expanded into GMP upscaling of nanoparticle therapies and contributing to pan-European PDX infrastructure networks. This signals a hospital moving from internal research excellence toward becoming a node in distributed translational oncology networks.

Moving from standalone cancer research toward integration into European translational oncology infrastructure and clinical-stage nanomedicine — a strong partner for consortia needing clinical trial sites or PDX model access.

How they like to work

With 1 coordinated project (AVATAR, their largest at nearly EUR 2M) and 2 participations, they demonstrate capacity to lead ambitious research but typically contribute as a specialist clinical partner. Their 29 unique partners across 11 countries indicate broad European reach rather than a closed circle. For potential collaborators, this means a hospital comfortable both driving a project and slotting into large consortia as the clinical/translational anchor.

Connected to 29 distinct partners across 11 countries, indicating a well-networked hospital for its size. Their partnerships span research institutions, nanomedicine developers, and PDX infrastructure providers across Western and Southern Europe.

What sets them apart

What sets Fuenlabrada apart is the combination of a public hospital environment with deep expertise in patient-derived xenograft models and direct involvement in nanomedicine clinical translation. Unlike pure research institutes, they bring clinical trial capability and patient access. Their ERC Advanced Grant coordination (AVATAR) demonstrates recognized scientific leadership in personalized pancreatic cancer treatment — a rare distinction for a non-university hospital.

Highlights from their portfolio

• AVATAR
  ERC Advanced Grant coordinated by the hospital (EUR 2M) — rare for a public hospital to lead an ERC project, focused on personalized pancreatic cancer treatment via genomics and mouse avatar models.
• NoCanTher
  Directly bridges nanomedicine manufacturing (GMP upscaling of magnetic nanoparticles) with clinical application, positioning the hospital at the frontier of cancer nanotherapy translation.
• EDIReX
  Part of a pan-European distributed infrastructure for patient-derived xenografts — small funding share (EUR 16K) but strategically important for network positioning in translational oncology.